BioCentury | Oct 19, 2009
Company News

Newron, Loyola University Medical Center deal

...all indications to be paid by Cornelli. Newron gained HF0420 through its 2008 acquisition of Hunter-Fleming Ltd....
BioCentury | Jul 14, 2008
Company News

Merrion board of directors update

Merrion Pharmaceuticals plc (ISE:3MP), Dublin, Ireland Business: Drug delivery Hired: John Fox as chief development officer, formerly COO at Hunter Fleming Ltd. WIR Staff...
BioCentury | May 19, 2008
Company News

Hunter-Fleming, Newron deal

...announced acquisition of Hunter-Fleming for E8 million ($12.4 million) in stock (see BioCentury, Feb. 18). Hunter-Fleming Ltd....
BioCentury | Mar 10, 2008
Clinical News

HF0220: Phase IIa ongoing

...interim review of safety data. Hunter-Fleming is being acquired by Newron (see BioCentury, Feb. 18). Hunter-Fleming Ltd....
BioCentury | Feb 21, 2008
Cover Story

Exploiting a window into AD

...target early steps in b-amyloid-related pathology. Therapeutic approach Company Product Description Status in AD Anti-inflammatory Hunter-Fleming Ltd....
BioCentury | Feb 18, 2008
Finance

Ebb & Flow

...19%) to CHF35.10 last week after the company said it will acquire fellow neurology company Hunter-Fleming...
BioCentury | Feb 18, 2008
Strategy

For want of a horse. . .

...to accelerate its development into a sustainable business. Despite having three compounds in the clinic, Hunter-Fleming...
...month for a mere E25 million ($37 million) in stock. In the spring of 2006, Hunter-Fleming...
...sentiment," Hunter-Fleming CEO Mike Capaldi told BioCentury. Part of the problem, according to Capaldi, was Hunter-Fleming's...
BioCentury | Feb 18, 2008
Company News

Hunter-Fleming, Newron deal

...Neurology company Newron will acquire Hunter-Fleming for E8 million ($11.6 million) in stock, plus up to...
...million ($11.6 million) in stock, plus up to E17 million ($25.2 million) in stock milestones. Hunter-Fleming’s...
...expected to start a Phase II trial to treat rheumatoid arthritis (RA) in late 2008. Hunter-Fleming...
BioCentury | Feb 12, 2008
Company News

Newron acquiring Hunter-Fleming

...will be eligible for milestones of up to EUR 17 million ($24.7 million) in stock. Hunter-Fleming's...
BioCentury | Jul 9, 2007
Clinical News

Hunter-Fleming preclinical data

...halved. HF0220 is an oral cytoprotective steroid currently in Phase IIa trials for Alzheimer's disease. Hunter-Fleming Ltd....
Items per page:
1 - 10 of 20
BioCentury | Oct 19, 2009
Company News

Newron, Loyola University Medical Center deal

...all indications to be paid by Cornelli. Newron gained HF0420 through its 2008 acquisition of Hunter-Fleming Ltd....
BioCentury | Jul 14, 2008
Company News

Merrion board of directors update

Merrion Pharmaceuticals plc (ISE:3MP), Dublin, Ireland Business: Drug delivery Hired: John Fox as chief development officer, formerly COO at Hunter Fleming Ltd. WIR Staff...
BioCentury | May 19, 2008
Company News

Hunter-Fleming, Newron deal

...announced acquisition of Hunter-Fleming for E8 million ($12.4 million) in stock (see BioCentury, Feb. 18). Hunter-Fleming Ltd....
BioCentury | Mar 10, 2008
Clinical News

HF0220: Phase IIa ongoing

...interim review of safety data. Hunter-Fleming is being acquired by Newron (see BioCentury, Feb. 18). Hunter-Fleming Ltd....
BioCentury | Feb 21, 2008
Cover Story

Exploiting a window into AD

...target early steps in b-amyloid-related pathology. Therapeutic approach Company Product Description Status in AD Anti-inflammatory Hunter-Fleming Ltd....
BioCentury | Feb 18, 2008
Finance

Ebb & Flow

...19%) to CHF35.10 last week after the company said it will acquire fellow neurology company Hunter-Fleming...
BioCentury | Feb 18, 2008
Strategy

For want of a horse. . .

...to accelerate its development into a sustainable business. Despite having three compounds in the clinic, Hunter-Fleming...
...month for a mere E25 million ($37 million) in stock. In the spring of 2006, Hunter-Fleming...
...sentiment," Hunter-Fleming CEO Mike Capaldi told BioCentury. Part of the problem, according to Capaldi, was Hunter-Fleming's...
BioCentury | Feb 18, 2008
Company News

Hunter-Fleming, Newron deal

...Neurology company Newron will acquire Hunter-Fleming for E8 million ($11.6 million) in stock, plus up to...
...million ($11.6 million) in stock, plus up to E17 million ($25.2 million) in stock milestones. Hunter-Fleming’s...
...expected to start a Phase II trial to treat rheumatoid arthritis (RA) in late 2008. Hunter-Fleming...
BioCentury | Feb 12, 2008
Company News

Newron acquiring Hunter-Fleming

...will be eligible for milestones of up to EUR 17 million ($24.7 million) in stock. Hunter-Fleming's...
BioCentury | Jul 9, 2007
Clinical News

Hunter-Fleming preclinical data

...halved. HF0220 is an oral cytoprotective steroid currently in Phase IIa trials for Alzheimer's disease. Hunter-Fleming Ltd....
Items per page:
1 - 10 of 20